As a quantum scientist, I specialize in simulating large biomolecules using quantum mechanics. My research aims to improve the precision of molecular modeling by exploring the intricate relationships between electronic properties and molecular behavior. The goal is to leverage advanced physics techniques to enhance drug development processes.

Early in my physics career, I joined a team at the non-profit institute FIDIC in Colombia, focusing on synthetic vaccine design. I contributed to quantum mechanics research on amino acids, peptides, and proteins. Graduating from Dalhousie University in 2011, I published papers on novel methods for studying noncovalent interactions and peptide stability. After my initial postdoctoral work on non-covalent interactions, I returned to FIDIC, conducting pioneering research on ligand-protein binding simulations and the structural evolution of amino acids.

In my current role as a Senior Researcher at the Ontario Institute for Cancer Research (OICR), I integrate quantum mechanics, machine learning, and advanced computing to develop innovative hybrid solutions for computer-aided drug discovery. Recently, I led the creation of a computational platform for large-scale virtual screening, optimizing speed and accuracy. During my first year at OICR, I secured a $200k grant as a co-principal investigator for a transformative quantum-powered drug discovery project, leading to the establishment of the spinoff company, QuAccel. Recently, I graduated from the Executive Institute Cohort VI of the adMare Academy C-suite program.

With a proven track record in funding acquisition, intellectual property development, and advanced quantum simulations, I am committed to advancing scientific exploration and fostering collaboration among forward-thinking researchers. My overarching goal is to utilize my experience to drive innovation in quantum computing, drug discovery, and molecular simulations, pushing the boundaries of scientific discovery.